tradingkey.logo

Cardiff Oncology Inc <CRDF.OQ> expected to post a loss of 19 cents a share - Earnings Preview

ReutersApr 28, 2025 11:23 AM
  • Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to show a fall in quarterly revenue when it reports results on April 30 (estimated) for the period ending March 31 2025

  • The San Diego California-based company is expected to report a 53.0% decrease in revenue to $96.43 thousand from $205 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 19 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 0.7% in the last three months. ​

  • Wall Street's median 12-month price target for Cardiff Oncology Inc is $14.00​, above​ its last closing price of $2.88. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.23

-0.24

-0.22

Beat

9

Sep. 30 2024

-0.27

-0.27

-0.25

Beat

7.4

Jun. 30 2024

-0.25

-0.26

Missed

-5.1​

Mar. 31 2024

-0.25

-0.25

-0.22

Beat

11.1

​​Dec. 31 2023

-0.27

-0.28

-0.21

Beat

24.3

Sep. 30 2023

-0.28

-0.28

-0.22

Beat

22.8​

Jun. 30 2023

-0.28

-0.26

-0.25

Beat

3.5

Mar. 31 2023

-0.22

-0.23

-0.25

Missed

-10.6

This summary was machine generated April 28 at 11:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI